For precision medicine-based clinical practice, modulating the TME by targeting the CCL11/CCR3 signaling circuit may attenuate the aggressiveness of cancer cells and offer a novel therapeutic strategy to improve the prognosis in patients with HNC. This evidence concerns the gene CCR3 and cancer.